US Airways Is on a ...
Health Care: Health Services
BG Medicine Inc. (BGMD: NASDAQ)
$1.83 0.15 | 8.93%
05/21/13 - 04:00 PM ET
Company Income Statement
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Sales | 2.82M | 1.63M | 819.00K | 8.49M |
| Cost of Sales | 684.00K | 199.00K | 246.00K | 7.68M |
| Gross Operating Profit | 2.13M | 1.44M | 573.00K | 812.00K |
| Selling, General, and Administrative Expenses | 17.00M | 10.50M | 8.10M | 7.52M |
| Research & Development | 7.58M | 8.00M | 6.54M | 8.53M |
| Operating Income before D & A (EBITDA) | -22.46M | -17.06M | -14.07M | -15.24M |
| Depreciation & Amortization | 273.00K | 420.00K | 540.00K | 753.00K |
| Interest Income | 22.00K | 31.00K | 5.00K | 121.00K |
| Other Income - Net | 20.00K | -39.00K | 231.00K | -26.00K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -22.69M | -17.49M | -14.37M | -15.89M |
| Interest Expense | 1.08M | 89.00K | 2.79M | 244.00K |
| Pre-Tax Income | -23.77M | -17.58M | -17.16M | -16.14M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | -23.77M | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | -23.77M | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -23.77M | -17.58M | -17.16M | -16.14M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-23.77M | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -23.77M | -118.00K | -1.03M | 0.00 |
| Basic EPS from Continuing Ops. | -1.18 | -1.00 | -6.12 | -1.29 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -1.18 | -1.00 | -6.12 | -1.29 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -1.18 | -1.00 | -6.12 | -1.29 |
| Basic Normalized Net Income/Share | -1.18 | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -1.18 | -1.00 | -6.12 | -1.29 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -1.18 | -1.00 | -6.12 | -1.29 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -1.18 | -1.00 | -6.12 | -1.29 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
-1.18 | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with BGMD
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks With Big Insider Buy...
- ContributorUnder-$10 Setting Up To Tra...
- Contributor8 Health Care Stocks With R...
Latest BGMD Headlines from TheStreet
- 8 Stocks Under $10 Trending Sharply Higher 05.14.13 | 11:05 pm
- BG Medicine, Inc. Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 05.10.13 | 05:05 pm
- BG Medicine Appoints Dr. Paul Sohmer As Chief Executive Officer 05.09.13 | 07:05 am
- BG Medicine Reports 2013 First Quarter Financial Results 05.09.13 | 07:05 am
- Trenton Health Team Adopts Novel Diagnostic Tool, BGM Galectin-3(R) Test, To Reduce Hospital Readmissions 05.08.13 | 07:05 am
- BG Medicine To Announce First Quarter 2013 Financial Results And Host Conference Call On Thursday, May 9, 2013 05.02.13 | 08:05 am
- BG Medicine Welcomes CE Mark For Galectin-3 Test 04.10.13 | 08:04 am
- BG Medicine Reports Fourth Quarter And Full Year 2012 Financial Results And Provides 2013 Outlook 03.13.13 | 07:03 am
- BG Medicine To Announce Fourth Quarter And Year-End 2012 Financial Results And Host Conference Call On Wednesday, March 13, 2013 03.06.13 | 08:03 am
- BG Medicine Highlights Role Of Galectin-3 Testing In Combating Hospital Readmissions At The American College Of Cardiology's (ACC) 62nd Annual Scientific Session & Expo 03.06.13 | 08:03 am
Press Releases for BGMD
- Abbott's Galectin-3 Test Provides Doctors In Europe With New Tool For Assessing The Prognosis Of Chronic Heart Failure Patients - PR Newswire 04.10.13 | 08:04 am
- Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability Of Galectin-3 Testing Service In Partnership With BG Medicine - PR Newswire 03.24.11 | 08:03 am
- BG Medicine Announces Exercise Of Underwriters’ Over-Allotment Option And Closing Of Initial Public Offering - Business Wire 02.09.11 | 04:02 pm
- BG Medicine Announces Pricing Of Initial Public Offering - Business Wire 02.04.11 | 08:02 am
Partner Headlines for BGMD
- Pre-Market Most Active for Dec 12, 2012 : TLAB, QQQ, NRF, STM, BAC, NOK, LLY, AIG, SIRI, BGMD, FB, AAPL - NASDAQ 12.12.12 | 01:12 pm
- 4 Undervalued And Technically Oversold Healthcare Penny Stocks Poised To Bounce - Seeking Alpha 11.20.12 | 09:11 am
- UPDATE: Ladenburg Thalmann Raises PT to $16.50 on BG Medicine - Benzinga 02.14.12 | 01:02 pm
- Market Update - Benzinga 01.09.12 | 09:01 am
